je.st
news
Home
› Jazz Pharmaceuticals Plc And Concert Pharmaceuticals Announce Worldwide Licensing Agreement To Develop And Commercialize Deuterium-Modified Sodium Oxybate
Jazz Pharmaceuticals Plc And Concert Pharmaceuticals Announce Worldwide Licensing Agreement To Develop And Commercialize Deuterium-Modified Sodium Oxybate
2013-02-26 17:15:00| drugdiscoveryonline Home Page
Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. recently announced an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323
Tags: agreement
develop
worldwide
jazz
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||